The top 100 bio­phar­ma ven­ture in­vestors at the mega­bil­lions deal ta­ble

The VC crowd took a step back last year, but nev­er­the­less main­tained a fu­ri­ous pace of new in­vest­ments in ther­a­peu­tic tech plat­forms and biotech star­tups. And the top 100 play­ers com­plete­ly dom­i­nat­ed the mega­bil­lions game.

Just look­ing at the num­ber of deals done by each of the top 100, Or­biMed came in at the top, with 20, fol­lowed by Alexan­dria (18), Per­cep­tive (16) and the ubiq­ui­tous RA Cap­i­tal at 16. It’s im­pos­si­ble to say ex­act­ly how much they in­vest­ed in to­tal — those num­bers are on­ly rarely pro­vid­ed — but it is clear from the num­bers as­sem­bled by Chris Doko­ma­ji­lar at Deal­For­ma who’s most like­ly to be found sit­ting at the ta­ble dur­ing the go-go days of biotech in­vest­ing.

Doko­ma­ji­lar tracked $14.06 bil­lion in biotech ven­ture in­vest­ing last year, a dip from the fren­zied pace of $16.02 bil­lion in 2018 and more than $10 bil­lion high­er than he record­ed for 2010, as the econ­o­my was re­cov­er­ing from a pro­found eco­nom­ic cri­sis.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER